# Achieve Life Sciences, Inc.: overview ACHV · Nasdaq · CIK 949858 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/achv.md) · [Financials](/companies/achv/financials.md) · [Filings](/companies/achv/filings.md) · [Insiders](/companies/achv/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.36)](/filings/0001193125-25-268074.md) | not reported | [(0.37)](/filings/0001193125-26-218177.md) | [(0.37)](/filings/0001193125-26-344624.md) | [(0.28)](/filings/0001193125-25-268074.md) | not reported | [(0.19)](/filings/0001193125-26-218177.md) | [(0.80)](/filings/0001193125-26-344624.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.08)](/filings/0000950170-24-038049.md) | [(4.00)](/filings/0000950170-25-036831.md) | [(1.50)](/filings/0001193125-26-120690.md) | [(1.24)](/filings/0001193125-26-120690.md) | [(1.25)](/filings/0001193125-26-120690.md) | | Free cash flow | $m | not reported | not reported | [(24.5)](/filings/0001193125-26-120690.md) | not reported | [(49.5)](/filings/0001193125-26-120690.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/achv/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $49.7m | 7,614,836 | | New +7,614,836 | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $44.9m | 6,877,580 | | New +6,877,580 | | [venBio Partners LLC](/funds/1776382.md) | 2026-06-30 | $38.6m | 5,914,720 | | New +5,914,720 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $35.4m | 5,425,000 | | New +5,425,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $34.4m | 5,272,017 | | Added +4,832,657 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $32.3m | 4,953,220 | | Added +584,027 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $32.3m | 4,951,856 | | New +4,951,856 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $27.0m | 4,140,812 | | Added +1,936,098 | | [Propel Bio Management, LLC](/funds/1969764.md) | 2026-06-30 | $26.3m | 4,034,018 | | Added +247,593 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $24.6m | 3,770,313 | | Added +2,751,032 | ## Recent filings [All 1,010 filings](/companies/achv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 20:49 ET | [8-K](/filings/0001193125-26-410781.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-410781 | | 2026-08-14 | 20:09 ET | [8-K](/filings/0001193125-26-352229.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-352229 | | 2026-08-11 | 20:09 ET | [10-Q](/filings/0001193125-26-344624.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344624 | | 2026-08-11 | 20:04 ET | [8-K](/filings/0001193125-26-344571.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344571 | | 2026-07-06 | 20:06 ET | [8-K](/filings/0001193125-26-296174.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-296174 | | 2026-06-08 | 20:06 ET | [DEF 14A](/filings/0000949858-26-000006.md) | Proxy statement, period 2026-06-08 | 0000949858-26-000006 | | 2026-06-02 | 12:51 ET | [8-K](/filings/0001193125-26-252624.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-252624 | | 2026-05-12 | 11:21 ET | [10-Q](/filings/0001193125-26-218177.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218177 | | 2026-05-12 | 11:20 ET | [8-K](/filings/0001193125-26-218175.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-218175 | | 2026-04-30 | 20:20 ET | [10-K/A](/filings/0001193125-26-197402.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-197402 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-120690.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 949858 - Tickers: ACHV - Exchange: Nasdaq - SIC code: 2835 In Vitro & In Vivo Diagnostic Substances - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.